| abstract |
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof that selectively bind to complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The present application also provides methods of using these inhibitors, eg, to inhibit TGFβ activation and to treat a subject suffering from a TGFβ-related disorder, such as a fibrotic condition. Also provided are methods of selecting a context-dependent or context-independent isotype-specific TGFβ inhibitor for a subject in need thereof. |